Remus Pharmaceuticals Reports Strong H1 FY27 Results with 53.45% Consolidated Revenue Growth
Remus Pharmaceuticals Ltd · Press Release · 03 Nov 2026, 9:46 pm
Remus Pharmaceuticals Reports Strong H1 FY27 Results with 53.45% Consolidated Revenue Growth Remus Pharmaceuticals reported H1 FY27 consolidated revenue of ₹614.12 Cr, up 53.45% YoY and 35.44% vs H2 FY26. Consolidated EBITDA rose 11.22% YoY to ₹29.93 Cr, while PAT grew 14.22% YoY to ₹24.66 Cr, impacted by setup and operating costs across Bolivia, Guatemala, and Espee GCTS subsidiaries. Standalone revenue jumped 32.51% YoY to ₹62.08 Cr, with PAT expanding 56.37% YoY to ₹18.81 Cr. Key operational milestones include securing Semaglutide approvals, winning a 24-product tender in Bolivia, and obtaining DIGEMID plant approval in Peru.
Original exchange filing (PDF)
More announcements from Remus Pharmaceuticals Ltd
- Remus Pharmaceuticals Limited has informed the Exchange about Transcript · 06 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Audio Recording · 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Investor Presentation · 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 07-Nov-2026. · 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Rs. 1.00 per equity share. · 03 Nov 2026
- Remus Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 03, 2026 · 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet · 29 Oct 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Dividend/Other business. · 03 Nov 2026
